Categories: Canada

Stock in Tylenol’s parent company rallies after Trump’s unproven claims – National


Shares of Tylenol maker Kenvue bounced back sharply before the opening bell a day after U.S. President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism.

“Don’t take Tylenol,” Trump instructed pregnant women around a dozen times during the White House news conference Monday, also urging mothers not to give their infants the drug, known by the generic name acetaminophen in the U.S. or paracetamol in most other countries.

Shares of the New Jersey consumer brands company tumbled 7.5 per cent Monday. Shares have regained most of those losses early Tuesday in premarket trading.

The announcement, which appeared to rely on existing studies rather than significant new research, arrives as Health and Human Services Secretary Robert F. Kennedy Jr., a vaccine skeptic, advances the Make America Healthy Again movement that has focused on what it sees as potential causes of autism.

Story continues below advertisement




U.S. will identify cause of ‘autism epidemic’ by September, Kennedy says


Kenvue disputed any link between the drug and autism this week and warned that if pregnant mothers don’t use Tylenol when in need, they could face a dangerous choice between suffering fevers or using riskier alternatives.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.

Kenvue was spun off from Johnson & Johnson in 2023. Aside from Tylenol, the consumer health company makes Band-Aids, Listerine and other household brand names.

Citi Investment Research analyst Filippo Falorni wrote that he sees a limited risk of new lawsuits after Trump’s announcement, but thinks “there could be risk to Tylenol consumption given the negative headlines.”

The company has fought hundreds of lawsuits related to the product and its alleged ties to autism, but most have been dismissed.

The analyst anticipates a positive reaction for Kenvue’s stock at the opening bell on Tuesday given the lack of new scientific evidence.

Story continues below advertisement

Shares of Kenvue Inc., based in Summit, New Jersey, climbed over seven per cent in premarket trading.


&copy 2025 The Canadian Press



Source link

admin2

Share
Published by
admin2

Recent Posts

Complex Problems Require Custom Solutions, Part 2

By Dan Zolet, CFA A couple of months ago, we discussed in our Strategic View…

40 minutes ago

Three years of the West Bank’s ‘third Nakba’ | Israel-Palestine conflict News

Rammun, occupied West Bank – Fresh off the seventh forced displacement of his central West…

54 minutes ago

Bitcoin Bear Would Be Record Shallow If $60,000 Was The Low

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure Glassnode has…

1 hour ago

Red Deer teens face assault charges after attack caught on camera

Two Red Deer, Alta., teens are facing assault charges after an attack on a 14-year-old…

2 hours ago

Widespread power outages in Western Manitoba as wind wreaks havoc on crews

Manitoba Hydro says conditions have become so poor Thursday night, they are unable to work…

5 hours ago

Private Equity Premia in a Public Equity Wrapper? Goldman’s Approach

Private equity is a longtime white whale for many investors and advisors. With its ability…

6 hours ago